一种实验性阿尔茨海默症药丸让高风险患者的记忆力减慢了52%,降低了脑萎缩率,为目前的治疗提供了更安全、口服的替代方法。 An experimental Alzheimer’s pill slowed memory decline by 52% in high-risk patients and reduced brain shrinkage, offering a safer, oral alternative to current treatments.

根据对临床试验的重新分析, 一种实验性阿尔茨海默病药物valiltramiprosate (ALZ-801) 在一个由125名50岁或以上的轻度记忆障碍和遗传风险的患者组成的小组中减缓了52%的认知衰退. An experimental Alzheimer’s drug, valiltramiprosate (ALZ-801), slowed cognitive decline by 52% in a subgroup of 125 people aged 50 or older with mild memory problems and a genetic risk for the disease, according to a reanalysis of a clinical trial. 在对记忆至关重要的河马坎普斯地区,参与者的大脑萎缩率也下降了18%。 Participants also had 18% less brain atrophy in the hippocampus, a memory-critical region. 与目前分解氨基甲状腺的四类治疗不同,ALZ-801是一种防止氨基甲状腺瘤的每天两次的避孕药,有可能减少严重的副作用,如脑肿胀——特别是对那些具有两份APOE4基因的人特别有益。 Unlike current IV treatments that break down amyloid plaques, ALZ-801 is a twice-daily pill that prevents amyloid clumping, potentially reducing serious side effects like brain swelling—especially beneficial for those with two copies of the APOE4 gene. 这项研究由4 700万加元的NIH赠款资助,在《毒品》杂志上发表,表明一些患者在试验后继续保持认知稳定性。 The study, funded by a $47 million NIH grant and published in Drugs, showed continued cognitive stability in some patients beyond the trial. 虽然小分组限制结论,但该药物的口述形式和安全简介表明它有可能成为一个更安全、更方便的替代办法。 While the small subgroup limits conclusions, the drug’s oral form and safety profile suggest potential as a safer, more accessible alternative.